Omega Fund Management has reduced its stake in Alumis (ALMS), selling 411,968 shares valued at approximately $10.3 million, according to an SEC filing dated May 15, 2026. Following this transaction, Omega’s remaining position in Alumis stands at 241,255 shares, reflecting a decrease in value of $1.06 million from the previous quarter. Despite this reduction, Alumis remains a notable component of Omega’s portfolio, accounting for 3.3% of its 13F AUM.
This divestment comes after Alumis shares surged 327% over the past year, significantly outperforming the S&P 500’s 25% gain. The company, focused on developing therapies for autoimmune diseases, is poised for potential growth with promising clinical data and plans for an FDA submission later this year. However, it also reported a substantial quarterly net loss of $93.1 million, indicating ongoing high research expenditures.
Investors should view Omega’s sale as a strategic move to manage exposure rather than a loss of confidence, while closely monitoring Alumis’s ability to translate clinical successes into commercial viability in a competitive biotech landscape.
Source: fool.com